Investor · 1 deal
Every published round OrbiMed took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies OrbiMed has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Azura Ophthalmics | 23 Oct 2020 | 1 | 0 |
Fund closes reported for OrbiMed, as distinct from the investments it has made.
Companies OrbiMed has backed that another company then bought. An exit for the holding, not a deal OrbiMed did.
Stories naming OrbiMed. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital's blog republishes an AFR report on Azura Ophthalmics' encouraging phase 2 dry-eye results, recalling the Israel-founded biotech's US$38 million raised, among it a US$16 million round that Brandon Capital's fund co-led.
Azura Ophthalmics reports positive phase two results for its dry eye ointment and moves toward registration studies; the Brandon Capital-backed biotech has raised US$38 million, including a US$16 million round co-led by MRCF.
Eye-disease drug developer Azura Ophthalmics announced a $28 million round from existing backers including MRCF, OrbiMed, TPG Biotech and Ganot Capital, funding registration studies of its dry eye treatment candidate.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio